<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101968</url>
  </required_header>
  <id_info>
    <org_study_id>16451</org_study_id>
    <nct_id>NCT04101968</nct_id>
  </id_info>
  <brief_title>The GBA Multimodal Study in Parkinson's Disease</brief_title>
  <official_title>Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacific Parkinson's Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simon Fraser University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silverstein Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pacific Parkinson's Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to analyze the molecular and clinical mechanisms of the relationship between&#xD;
      the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced&#xD;
      neuroimaging techniques called PET (positron emission tomography) to study the accumulation&#xD;
      of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people&#xD;
      with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will&#xD;
      also use a technology-based assessment to study the typing patterns as possible biomarkers of&#xD;
      early motor dysfunctions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing&#xD;
      Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and&#xD;
      dementia. Cognitive problems in people with PD is related to dysfunction of the brain&#xD;
      chemical acetylcholine and likely to the accumulation of the tau protein in the brain.&#xD;
      Another observation in previous studies is that analyzing the patterns of typing into a&#xD;
      computer can help differentiate healthy people from people with PD.&#xD;
&#xD;
      Hypothesis: The investigators hypothesize that people with GBA-related PD will have higher&#xD;
      acetylcholine dysfunction and tau accumulation compared with non-GBA patients, and that these&#xD;
      changes may start in the asymptomatic phase (i.e., people with the mutation but without&#xD;
      symptoms of PD). The investigators also believe that the investigators will be able to detect&#xD;
      subjects with higher degree of dopamine loss just by analyzing the way they type into a&#xD;
      computer.&#xD;
&#xD;
      Study Design: The investigators will recruit 25 subjects with a GBA mutation (10 subjects&#xD;
      with PD and 15 asymptomatic carriers). All the participants will have a clinical evaluation&#xD;
      and a typing session, and subsequently will undergo a brain MRI and three PET scans with a&#xD;
      tau tracer, an acetylcholine tracer, and a dopaminergic tracer. A blood sample will also be&#xD;
      taken for the analysis of GCase (the enzyme related to the GBA mutation).&#xD;
&#xD;
      Impact on Diagnosis/Treatment of Parkinson's Disease: The results will help understand the&#xD;
      changes that take place in the brain of people with GBA-related Parkinson's disease, and&#xD;
      hopefully will shed light also on the pathophysiology of non-GBA-related Parkinson's, as well&#xD;
      as on the molecular correlates of cognitive decline, especially in its early stage. The&#xD;
      typing data along with dopaminergic imaging will clarify the possible role of using typing&#xD;
      patterns to identify subjects with early stage Parkinson's disease.&#xD;
&#xD;
      Next Steps for Development: The findings of this study may help identify biomarkers for&#xD;
      cognitive decline in early Parkinson's disease, with a potential role in clinical trials.&#xD;
      Also, if the hypothesis on the typing is confirmed, this approach may be studied in larger&#xD;
      cohorts for early diagnosis of Parkinson's in other at-risk populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acetylcholinesterase activity</measure>
    <time_frame>baseline</time_frame>
    <description>11C-PMP PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tau protein deposition</measure>
    <time_frame>baseline</time_frame>
    <description>11C-PBB3 PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dopaminergic denervation</measure>
    <time_frame>baseline</time_frame>
    <description>11C-DTBZ PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neuroQWERTY index</measure>
    <time_frame>baseline</time_frame>
    <description>Typing analysis</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>GBA Gene Mutation</condition>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>GBA-PD</arm_group_label>
    <description>People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic GBA</arm_group_label>
    <description>Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <description>3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.</description>
    <arm_group_label>Asymptomatic GBA</arm_group_label>
    <arm_group_label>GBA-PD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>neuroQWERTY</intervention_name>
    <description>Analysis of free-text typing in a computer and/or a touch-screen device.</description>
    <arm_group_label>Asymptomatic GBA</arm_group_label>
    <arm_group_label>GBA-PD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with a known pathogenic GBA gene mutation with or without PD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;&#xD;
&#xD;
          -  age 18 to 80 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  co-occurrence of other neurological disorders;&#xD;
&#xD;
          -  implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic&#xD;
             implants or devices);&#xD;
&#xD;
          -  severe claustrophobia;&#xD;
&#xD;
          -  intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);&#xD;
&#xD;
          -  ongoing treatment with cholinergic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Matarazzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Parkinson's Research Centre | University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Jon Stoessl, CM, MD, FRCPC, FCAHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Parkinson's Research Centre | University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Matarazzo, MD</last_name>
    <phone>+1-604-822-7764</phone>
    <email>michele.matarazzo@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Brodsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cyrus P Zabetian, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Parkinson's Research Centre | University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jess McKenzie</last_name>
      <phone>+1-604-822-7764</phone>
      <email>jess.mckenzie@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Monica Yenko</last_name>
      <phone>+1-604-827-1315</phone>
      <email>monica.yenko@ubc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>A Jon Stoessl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

